Regeneron's baloncibart reduces standing heart rate response in Phase 2 POTS trial

• Regeneron’s investigational baloncibart reduced excessive heart-rate increases upon standing in the Phase 2 PINNACLE trial for postural orthostatic tachycardia syndrome (POTS).
• A single higher dose improved orthostatic symptoms through four weeks; the lower dose’s heart-rate benefit was not sustained.
• Results were presented for the first time today at the American Autonomic Society’s annual meeting.
• Treatment was generally well tolerated, with mostly mild or moderate adverse events; two serious events occurred, but none prompted discontinuation.
• A potentially pivotal Phase 3 trial is planned for the first half of 2027; POTS has no FDA-approved treatments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121700PRIMZONEFULLFEED9876702) on November 12, 2026, and is solely responsible for the information contained therein.